当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2014年
35期
73-74
,共2页
白蛋白结合型紫杉醇%顺铂%晚期卵巢癌%腹腔灌注化疗
白蛋白結閤型紫杉醇%順鉑%晚期卵巢癌%腹腔灌註化療
백단백결합형자삼순%순박%만기란소암%복강관주화료
Albumin-bound paclitaxel%Cisplatin%Advanced ovarian cancer%Intraperitoneal chemotherapy
目的:探讨白蛋白结合型紫杉醇联合腹腔灌注顺铂在治疗老年晚期卵巢癌的疗效及安全性。方法回顾性分析晚期卵巢癌患者21例。采用白蛋白结合型紫杉醇80 mg/m 2静滴,d 1、8。DDP 40 mg腹腔热灌注,d 2、9,每3周重复1次,2个周期评价疗效。结果 CR 1例,PR 13例,SD 2例,PD 5例,总有效率(RR)66.7%,疾病控制率(DCR)71.2%,中位无进展生存期(PFS)10.1个月。常见不良反应为Ⅰ~Ⅱ骨髓抑制、Ⅰ~Ⅱ胃肠道反应及Ⅰ外周神经毒性。结论白蛋白结合型紫杉醇联合腹腔灌注化疗在治疗老年晚期卵巢癌疗效较好,老年患者耐受性好,值得临床进一步推广。
目的:探討白蛋白結閤型紫杉醇聯閤腹腔灌註順鉑在治療老年晚期卵巢癌的療效及安全性。方法迴顧性分析晚期卵巢癌患者21例。採用白蛋白結閤型紫杉醇80 mg/m 2靜滴,d 1、8。DDP 40 mg腹腔熱灌註,d 2、9,每3週重複1次,2箇週期評價療效。結果 CR 1例,PR 13例,SD 2例,PD 5例,總有效率(RR)66.7%,疾病控製率(DCR)71.2%,中位無進展生存期(PFS)10.1箇月。常見不良反應為Ⅰ~Ⅱ骨髓抑製、Ⅰ~Ⅱ胃腸道反應及Ⅰ外週神經毒性。結論白蛋白結閤型紫杉醇聯閤腹腔灌註化療在治療老年晚期卵巢癌療效較好,老年患者耐受性好,值得臨床進一步推廣。
목적:탐토백단백결합형자삼순연합복강관주순박재치료노년만기란소암적료효급안전성。방법회고성분석만기란소암환자21례。채용백단백결합형자삼순80 mg/m 2정적,d 1、8。DDP 40 mg복강열관주,d 2、9,매3주중복1차,2개주기평개료효。결과 CR 1례,PR 13례,SD 2례,PD 5례,총유효솔(RR)66.7%,질병공제솔(DCR)71.2%,중위무진전생존기(PFS)10.1개월。상견불량반응위Ⅰ~Ⅱ골수억제、Ⅰ~Ⅱ위장도반응급Ⅰ외주신경독성。결론백단백결합형자삼순연합복강관주화료재치료노년만기란소암료효교호,노년환자내수성호,치득림상진일보추엄。
Objective To evaluate the therapeutic efifcacy and the safety of albumin-bound paclitaxel combined with intraperitoneal injection in elderly patients with advanced ovarian cancer. Methods Retrospectively analysis 21 patients with advanced ovarian cancer who were received from February 2012 to February 2014. They were given albumin-bound paclitaxel (80 mg/m 2, ivgtt, d 1、8),and DDP (40 mg, d 2、9)with intraperitoneal peffusion. Every 3 weeks was a course of treatment. The efifcacy and side effects were evaluated after 2 courses of treatment. Results Numbers of complete response,partial response,stable disease progression disease of patients were 1, 13, 2 and 5 respectively. Of 21 patients, the RR was 66.7%, the DCR was 71.2%, the median PFS was 10.1 months. The most frequent treatment-ralated adverse events were myelosuppression, gastrointestinal reaction, and peripheral neuropathy. Conclusion Albumin-bound paclitaxel combined with intraperitoneal injection in advanced ovarian cancer is effective with minimal adverse reactions and can be tolerated by elderly patients, so it is worthy of clinical promotion.